Director/PDMR Shareholding

RNS Number : 4627C

e-Therapeutics plc

22 January 2018

 

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 22 January 2018 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 19 January 2018 it granted a total of 2,250,000 options over its ordinary shares of 0.1 pence each to Raymond Barlow, Chief Executive Officer and a Director of the Company, and Steve Medlicott, Finance Director, as follows:

Director	Number of options granted	Scheme under which options granted	Exercise price per share
Raymond Barlow	1,500,000	e-Therapeutics Performance Share Plan 2013 (One-Off Awards 2016)	16.76 pence
Steve Medlicott	750,000	e-Therapeutics Performance Share Plan 2013 (Enterprise Management Incentive Share Option Plan)	16.76 pence

The options are subject to the achievement of certain performance conditions and, in the event of those conditions being met, the options will vest on the following basis:

·      25% 6 months after the date of this award;

·      50% on the first anniversary of the award;

·      75% 18 months after the date of the award; and

·      100% on the second anniversary of the award.

If the conditions are not satisfied by the second anniversary (and one day) the award will lapse in its entirety.

Following this grant, Raymond Barlow holds a total of 7,000,000 options, and Steve Medlicott holds 2,750,000 options.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Raymond John Barlow
2	Reason for the notification
a)	Position/status	Chief Executive Officer/Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	1,500,000 options over ordinary shares at an exercise price of 16.76 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	19 January 2018
f)	Place of the transaction	LSE, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Steven Medlicott
2	Reason for the notification
a)	Position/status	Finance Director/Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	750,000 options over ordinary shares at an exercise price of 16.76 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	19 January 2018
f)	Place of the transaction	LSE, AIM

For further information, please contact:

Contacts:

e-Therapeutics plc Ray Barlow, Chief Financial Officer Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Deborah Bell	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.  

Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.

For more information about the Company, please visit www.etherapeutics.co.uk

 

END

 

 

DSHLFFILLDILFIT